Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Future of Bontalapetics
There is an even the corticosteroids that which are used for most of the autoimmune diseases are not useful at all. You get a little bit of success with very low doses of corticosteroid but if you increase your agribate disease so you can go that way. And you need a product which would be efficient and I think that for clinical preclinical reasons we have this type of thing with our arsenic formulation. So that is something which could also be developed and which is part of our pipeline. On the bontalapetics side, the cell repair side, what we would like to do is probably to go further and elsewhere than the T-bial fractures. And there
Transcript
Play full episode
